△ Mr. Ryu Hyung-sun, Chairman of Dasan Pharmaceutical Korea, and Mr. Dong Laishan, Chairman of Anhui Heyida Pharmaceutical, signing documents
Following the establishment of the Shenyang R&D Center in China in 2014, on June 20, 2024, Dasan Pharmaceutical Korea and Anhui Heyida Pharmaceutical Co., Ltd. held a signing ceremony in Shanghai to establish a joint venture. The two parties jointly invested to establish Anhui Heyida DASAN Pharmaceutical Co., Ltd., committed to deep cooperation in the pharmaceutical field.
△ Leaders from both companies shaking hands
The establishment of this joint venture marks a powerful alliance between the two companies, enabling them to fully leverage their respective advantages in the R&D, production, and sales of APIs and finished formulations to jointly explore domestic and international pharmaceutical markets.
△ Group photo of leaders of Anhui Heyida DASAN Pharmaceutical
△ Group photo with Dasan Pharmaceutical Korea partners who came to congratulate the signing ceremony
Since its establishment in 1996, Dasan Pharmaceutical Co., Ltd. has focused on the production of pharmaceutical intermediates. As the top company in Korea in fluidized bed-related technologies, it engages in contract manufacturing with numerous major Korean pharmaceutical companies.
Dasan Pharmaceutical's core technologies include fluidized bed coating technology for masking the bitter taste of active pharmaceutical ingredients (APIs) and fine particle coating technology. It is also concurrently developing drug release control technology and API synthesis technology. Recently, the company has been focusing on the development of a new generation of drug delivery—transdermal drug delivery technology. This transdermal drug delivery technology can be applied not only to pharmaceuticals but also to advanced functional cosmetics.
Anhui Heyida Pharmaceutical Co., Ltd.'s main business is the R&D, production, and sales of APIs and related products. Its main product categories include antiallergics, antithrombotics, antioxidants, anti-ulcer drugs, antivirals, antipyretics and analgesics, and UV absorbers. The company's main products are characterized by relatively complex structures, high R&D difficulty, high technical barriers, unique production processes, and high added value.
The company's core management team possesses over twenty years of industry experience, accumulating extensive R&D expertise and industrial chain resources. The company has established long-term, stable cooperative relationships with downstream clients. Its main products are ultimately sold in regulated overseas markets such as Japan, South Korea, Europe, and the United States, with end customers including many multinational corporations and other well-known pharmaceutical companies.
△ Ceremony site for the centralized project signing in Tianchang City
The establishment of this joint venture in Anhui Province has also received high attention from the Chuzhou municipal government. On June 17, Mr. Ryu Hyung-sun, Chairman of Dasan Pharmaceutical Korea, participated in the centralized signing ceremony for key projects in Chuzhou as part of the city's "Summer Offensive" investment promotion campaign for Tianchang.
Xu Jiwei, Secretary of the Chuzhou Municipal Committee; Wu Jin, Deputy Secretary of the Chuzhou Municipal Committee and Mayor; Wang Tuqiang, Director of the Standing Committee of the Chuzhou People's Congress; Jin Li, Deputy Secretary of the Chuzhou Municipal Committee; and Chuzhou leaders Sun Jun, Deng Jigai, Zhu Lin, along with He Jiaping, Deputy Director of the Standing Committee of the Chuzhou People's Congress and Secretary of the Tianchang Municipal Committee, witnessed the signing.
△ Group photo with He Jiaping, Deputy Director of the Standing Committee of the Chuzhou People's Congress and Secretary of the Tianchang Municipal Committee, and Du Yongbing, Deputy Secretary of the Tianchang Municipal Committee
On behalf of the Chuzhou Municipal Committee and Municipal Government, Xu Jiwei warmly welcomed the delegation of clients participating in the on-site signing ceremony. He stated that after this centralized signing, Chuzhou and Tianchang will further enhance services and provide comprehensive support, leveraging the "Ting Satisfying" business environment to ensure that enterprises develop comfortably, securely, and smoothly in Chuzhou. He also expressed hope that all companies would accelerate project construction to enable early commencement, rapid construction, and prompt production.
Chairman Ryu Hyung-sun stated: "In the future, we will continue to strive, not only to expand in the Chinese market but also to venture into overseas markets. I sincerely hope that the relevant government departments will give us more attention and support, making Tianchang, Chuzhou, and even the entire Anhui Province key regions for China's pharmaceutical industry."
On the same day, a groundbreaking ceremony for the joint venture was held in Tianchang City, Anhui Province. Lv Chuanhua, Secretary of the Party Working Committee and Director of the Management Committee of the Chuzhou High-tech Zone, along with senior executives from both companies, gathered together to witness this historic moment.
△ Ribbon-cutting ceremony for the commencement of Anhui Heyida DASAN Pharmaceutical
△ Groundbreaking ceremony for Anhui Heyida DASAN Pharmaceutical
In the future, the joint venture will focus on the pharmaceutical industry, striving to become a leading enterprise in the domestic and international pharmaceutical sectors. Adhering to the philosophy of benefiting humanity, the two parties will jointly build a new future for the pharmaceutical industry, injecting new vitality into the field.
Posting Date：2024-06-21
Views： 
Previous：
Back to List